Bayer (BAYN) Stock Rating Reaffirmed by Citigroup
Bayer (FRA:BAYN)‘s stock had its “buy” rating reaffirmed by Citigroup in a note issued to investors on Thursday.
BAYN has been the topic of a number of other reports. J P Morgan Chase & Co reaffirmed a “buy” rating on shares of Bayer in a research report on Tuesday, August 29th. set a €105.00 ($125.00) price objective on shares of Bayer and gave the company a “neutral” rating in a research report on Tuesday, August 29th. Barclays set a €105.00 ($125.00) price objective on shares of Bayer and gave the company a “sell” rating in a research report on Monday, November 6th. Jefferies Group set a €137.00 ($163.10) price objective on shares of Bayer and gave the company a “buy” rating in a research report on Tuesday, August 29th. Finally, Berenberg Bank set a €121.00 ($144.05) price objective on shares of Bayer and gave the company a “neutral” rating in a research report on Tuesday, August 29th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and fourteen have issued a buy rating to the company’s stock. Bayer presently has a consensus rating of “Buy” and an average price target of €122.19 ($145.46).
Bayer (FRA BAYN) opened at €104.70 ($124.64) on Thursday. Bayer has a 1 year low of €90.26 ($107.45) and a 1 year high of €123.82 ($147.40).
ILLEGAL ACTIVITY WARNING: This story was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.thecerbatgem.com/2017/12/09/bayer-bayn-stock-rating-reaffirmed-by-citigroup.html.
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and womens health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Receive News & Stock Ratings for Bayer AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer AG and related stocks with our FREE daily email newsletter.